Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

1V209 is a benzoic acid-modified purine that, when conjugated to polysaccharides or sterols, acts as a toll-like receptor 7 (TLR7) agonist.1,2 A variety of 1V209-polysaccharide conjugates, but not 1V209 alone, increase TNF-α secretion from RAW 264.7 macrophages and IL-6 secretion from bone marrow-derived dendritic cells (BMDCs; EC50s = 4.62-61.7 and 3.2-188 nM, respectively). Liposomes encapsulating 1V209-cholesterol conjugates decrease primary tumor weight, secondary tumor volume, and the number of secondary lung metastases, as well as increase tumor-associated CD8+ IFN-γ+ T cells and survival, in a CT26 colorectal cancer mouse model of tumor rechallenge and lung metastasis.2
WARNING This product is not for human or veterinary use.
1. Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides. Bioconjug. Chem. 26(8), 1713-1723 (2015).
2. Lymph-